GLP-1 Receptor Agonists (GLP1-RA) and Dipeptidyl peptidase 4 inhibitors (DPP4i) have been noted in various case reports and case control studies to be linked with certain AIBDs; however, their overall role in these diseases is not completely understood, despite the exponential increase in use...
To overcome the short half-life of endogenous GLP1 and to achieve therapeutic advantages, two approaches are being investigated; dipeptidyl peptidase-4 (DPP4) inhibitors, which prevent the breakdown of native GLP1, and the synthesis of GLP1 analogs with prolonged action [40]. Several strategies ...
GLP1-RA and SGLT2i Combination Treatment in Type 2 Diabetes Over recent years, both GLP1-RAs and SGLT2is have become guideline-recommended organ-protective treatments, both drug classes exhibiting potent cardiovascular and kidney protective effects [13]. While there are key differences, the indica...
Chronic kidney disease (CKD) is strongly associated with cardiovascular disease and is a significant risk factor for increased morbidity and mortality. In contrast, GLP-1 receptor (GLP-1R) activation has been shown to confer both renal and cardiovascular protection, though its relationship with CKD ...
1. Intestinal L cells-derived GLP-1 induce insulin secretion in response to meal intake. 2. Insulinotropic potency of GLP-1 decrease in T2DM. 3. GLP-1 receptor agonists and DPP4-inhibitor direct the T2DM therapies. 4. Increasing the endogenous production of GLP-1 through increasing the L-cel...
Here, we summarise clinical inertia as a key barrier to increased use of SGLT2i and GLP-1 RA in eligible, at-risk patients in post-CVOT diabetes care. By doing so, we hope to alert the community to the urgency of the cardiorenal crisis, and the need to do more to mitigate risk in...
The first DPP-IV inhibitor to become available for clinical use was Sitagliptin in 2006 which is also used in combination with Metformin and SGLT-2 inhibitors for glycaemic control. Other DPP-IV inhibitors, such as, Litagliptin, Saxagliptin are approved by U.S. FDA for glycaemic control ...
老年T2DM患者起始恩格列净对比DPP4i和GLP-1 RA对心血管结局的影响: 一项EMPRISE研究的亚组分析 提示:
Here, we summarise clinical inertia as a key barrier to increased use of SGLT2i and GLP-1 RA in eligible, at-risk patients in post-CVOT diabetes care. By doing so, we hope to alert the community to the urgency of the cardiorenal crisis, and the need to do more to mitigate risk in...
(2011) “Incretin effect: GLP-1, GIP, DPP4,” Diabetes Res Clin Pract. 93(Suppl 1):S32-S36. et al. (2011) “Incretin effect: GLP-1, GIP, DPP4,” Diabetes Res Clin Pract. 93(Suppl 1):S32-S36. Knudsen et al. (2000) “Potent derivatives of glucagon-like peptide-1 with ...